Eisai and Pfizer have decided not to appeal NICE’s decision on Alzheimer’s drugs and have called for an expedited review of guidance for the disease.
In June this year, NICE announced that the guidance remains unchanged despite recognising significant errors within their model. Eisai and Pfizer have decided not to appeal the decision, however, on the basis that NICE has promised to review the existing guidelines.
Nick Burgin, Managing Director of Eisai, commented: "While we shared the disappointment of many on hearing NICE’s decision, we have decided not to appeal. The fundamental reason for this is that on June 11th, Andrew Dillon, NICE Chief Executive, committed to commence a review of the existing guidance ‘as soon as possible’, as long as no appeals were received.
“It is therefore right that Eisai and Pfizer do all we can to allow NICE to honour its stated commitment and to take into account new data that have become available as well as advances in economic modelling techniques."
Eisai and Pfizer have stated that they are committed to working with NICE and call upon the Institute to provide a timeline for the review as a matter of urgency.